<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000455147">
  <TermName>17-dimethylaminoethylamino-17-demethoxygeldanamycin</TermName>
  <TermPronunciation>(17-dy-MEH-thul-uh-MEE-noh-EH-thul-uh-MEE-noh-17-dee-meh-THOK-see-gel-DA-nuh-MY-sin)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>17-DMAG. A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called geldanamycin analogs.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000715227" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;17-dimethylaminoethylamino-17-demethoxygeldanamycin&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000715226" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;17-dimetilaminoetilamino-17-demetoxigeldanamicina&quot;" language="es" id="_4"/>
  <SpanishTermName>17-dimetilaminoetilamino-17-demetoxigeldanamicina</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>17-DMAG. Sustancia en estudio para el tratamiento de cáncer. Pertenece a la familia de medicamentos que se llaman análogos de la geldanamicina.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2006-08-24</DateFirstPublished>
</GlossaryTerm>
